قارن الطرق

	مؤشر نوعية الحياة في طب الأمراض الجلدية للأطفال (cDLQI)	مقياس ميلانكوليا لجودة الحياة (MelasQoL)	مقياس Skindex-29 (أداة جودة الحياة لأمراض الجلد)
المجال	الأمراض الجلدية	الأمراض الجلدية	الأمراض الجلدية
العائلة	Process / pipeline	Process / pipeline	Process / pipeline
سنة النشأة	1995	2006	1997
صاحب الطريقة	Lewis-Jones MS, Finlay AY	Cestari TF, Hexsel D	Chren MM, Lasek RJ
النوع	Self-report (parent or child proxy)	Self-report	Self-report
المصدر التأسيسي	Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (cDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949.	Cestari TF, Hexsel D, Brandt FS, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL. Br J Dermatol. 2006;156(Suppl 3):13-20.	Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713.
الأسماء البديلة	cDLQI, Pediatric DLQI	Melasma-QoL	Skindex, Skindex-QoL
ذات صلة	3	3	1
الملخص	The Children's Dermatology Life Quality Index (cDLQI) is a pediatric-adapted version of the adult DLQI, measuring the impact of skin disease on quality of life in children and adolescents aged 4–16 years. Developed by Lewis-Jones and Finlay in 1995, it uses child-friendly language and addresses domains relevant to childhood (school, leisure, friendships, clothing) rather than work and adult relationships. cDLQI is the standard quality-of-life measure in pediatric dermatology trials and clinical practice.	MelasQoL is a disease-specific, patient-administered quality-of-life measure designed to assess the psychosocial burden of melasma, a common chronic disorder of symmetric facial hyperpigmentation. Developed by Cestari and colleagues in 2006, it captures the unique emotional and social impacts of a predominantly cosmetic condition that disproportionately affects women of color. MelasQoL is essential in clinical trials and observational studies of melasma treatments to ensure that efficacy encompasses meaningful quality-of-life outcomes.	Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.